Scientists find molecule in immune system that could help treat dangerous skin cancer

July 8, 2012 in Immunology

Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.

Their findings will be published online in the July 8, 2012 issue of Nature Medicine.

After observing mice without genes responsible for development of an immune cell called T helper cell 17 (TH17), researchers found that these mice had significant resistance to melanoma tumor growth, suggesting that blockade of the TH17 favored tumor inhibition. The researchers also noticed that the mice expressed high amounts of interleukin-9.

"These were unexpected results, which led us to examine a possible contribution of interleukin-9 to suppression." said Purwar.

The researchers next treated melanoma-bearing mice with T helper cell 9 (TH9), an immune cell that produces interleukin-9. They saw that these mice also had a profound resistance to melanoma growth. This is the first reported finding showing an anti-tumor effect of TH9 cells.

Moreover, the researchers were able to detect TH9 cells in both normal human blood and skin, specifically in skin-resident memory and memory T cells in . In contrast, TH9 cells were either absent or present at very low levels in human melanoma. This new finding paves the way for future studies that will assess the role of interleukin-9 and TH9 cells in therapy.

"Immunotherapy of cancer is coming of age, and there have been exciting recent results in patients with melanoma treated with drugs that stimulate the immune system," said Kupper. "We hope that our results will also translate to the treatment of melanoma patients, but much work still needs to be done."

According to the researchers, other cell-signaling molecules have been used in treating melanoma; however, this study is the first to investigate the role of interleukin-9 in melanoma tumor immunity.

Melanoma is the most dangerous form of skin cancer. The National Cancer Institute estimates that in 2012, there will be more than 76,000 new cases of melanoma in the United States and 9,180 deaths. Melanoma is curable if recognized and treated early.

Journal reference: Nature Medicine search and more info website

Provided by Brigham and Women's Hospital search and more info website

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.

Immunology created 23 hours ago | popularity 4.7 / 5 (19) | comments 8 | with audio podcast

Vitamin D could provide new and effective treatments for asthma

(Medical Xpress)—Scientists at King's College London have discovered that Vitamin D has the potential to significantly reduce the symptoms of asthma. The study, led by Professor Catherine Hawrylowicz from ...

Immunology created May 20, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Immune protein could stop diabetes in its tracks

Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.

Immunology created May 20, 2013 | popularity 5 / 5 (5) | comments 0 | with audio podcast

Stem-cell-based strategy boosts immune system in mice

Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells in the laboratory. The researchers showed that, in mice, ...

Immunology created May 16, 2013 | popularity 4.8 / 5 (5) | comments 0 | with audio podcast

Resistance to visceral leishmaniasis: New mechanisms involved

Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 ...

Immunology created May 16, 2013 | popularity not rated yet | comments 0


New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Researchers find genetic risk factor for pulmonary fibrosis

A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibros ...

Biomarkers discovered for inflammatory bowel disease

Using the Department of Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers have identified a number of biomarkers for inflammatory bowel disease (IBD), which could help with earlier diagnosis and ...

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

Post-approval TAVI registry shows high rates of device success at one year

One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...

Biodegradable stent proves non-inferior to drug-eluting stent

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...